Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 22:2020:2567957.
doi: 10.1155/2020/2567957. eCollection 2020.

Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches

Arwa A Mohammed  1   2 , Shaza W Shantier  1   3 , Mujahed I Mustafa  1 , Hind K Osman  1   4 , Hashim E Elmansi  1 , Isam-Aldin A Osman  1   5 , Rawan A Mohammed  6 , Fatima A Abdelrhman  1   7 , Mihad E Elnnewery  1   8 , Einas M Yousif  1 , Marwa M Mustafa  1 , Nafisa M Elfadol  1 , Alaa I Abdalla  1   9 , Eiman Mahmoud  1   10 , Ahmed A Yagaub  1   8 , Yassir A Ahmed  6 , Mohamed A Hassan  1   11
Affiliations

Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches

Arwa A Mohammed et al. J Immunol Res. .

Abstract

Background: Nipah belongs to the genus Henipavirus and the Paramyxoviridae family. It is an endemic most commonly found at South Asia and has first emerged in Malaysia in 1998. Bats are found to be the main reservoir for this virus, causing disease in both humans and animals. The last outbreak has occurred in May 2018 in Kerala. It is characterized by high pathogenicity and fatality rates which varies from 40% to 70% depending on the severity of the disease and on the availability of adequate healthcare facilities. Currently, there are no antiviral drugs available for NiV disease and the treatment is just supportive. Clinical presentations for this virus range from asymptomatic infection to fatal encephalitis.

Objective: This study is aimed at predicting an effective epitope-based vaccine against glycoprotein G of Nipah henipavirus, using immunoinformatics approaches.

Methods and materials: Glycoprotein G of the Nipah virus sequence was retrieved from NCBI. Different prediction tools were used to analyze the epitopes, namely, BepiPred-2.0: Sequential B Cell Epitope Predictor for B cell and T cell MHC classes II and I. Then, the proposed peptides were docked using Autodock 4.0 software program. Results and Conclusions. The two peptides TVYHCSAVY and FLIDRINWI have showed a very strong binding affinity to MHC class I and MHC class II alleles. Furthermore, considering the conservancy, the affinity, and the population coverage, the peptide FLIDRINWIT is highly suitable to be utilized to formulate a new vaccine against glycoprotein G of Nipah henipavirus. An in vivo study for the proposed peptides is also highly recommended.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
BepiPred linear prediction. Areas above the red line (threshold) are epitopes suggested to be binding to the B cells while the green areas are not.
Figure 2
Figure 2
Emini surface accessibility prediction. Areas above the red line (threshold) are epitopes suggested to be binding to the B cells while the green areas are not.
Figure 3
Figure 3
Kolaskar and Tongaonkar antigenicity prediction. Areas above the red line (threshold) are epitopes suggested to be binding to the B cells while the green areas are not.
Figure 4
Figure 4
The three phases of Materials and Methods.
Figure 5
Figure 5
Molecular docking of FLIDRINWI peptide of Nipah virus docked in HLA-A∗02:01 and visualized by UCSF Chimera X version 0.1.0.
Figure 6
Figure 6
The four potential peptides bound to MHC class I and MHC class II visualized by Chimera X version 0.1.0.
Figure 7
Figure 7
Molecular docking of TVYHCSAVY peptide of Nipah virus docked in HLA-A∗02:01 and visualized by UCSF Chimera X version 0.1.0.
Figure 8
Figure 8
Molecular docking of FAYSHLERI peptide of Nipah virus docked in HLA-A∗02:01 and visualized by UCSF Chimera X version 0.1.0. ∗D.S: Docking Side No.1.
Figure 9
Figure 9
Molecular docking of FAYSHLERI peptide of Nipah virus docked in HLA-A∗02:01 and visualized by UCSF Chimera X version 0.1.0. ∗D.S: Docking Side No.2.
See this image and copyright information in PMC

References

    1. Chattu V. K., Kumar R., Kumary S., Kajal F., David J. K. Nipah virus epidemic in southern India and emphasizing "One Health" approach to ensure global health security. Journal of Family Medicine and Primary Care. 2018;7(2):275–283. doi: 10.4103/jfmpc.jfmpc_137_18. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention (CDC) Outbreak of Hendra-like virus--Malaysia and Singapore, 1998-1999. Morbidity and Mortality Weekly Report. 1999;48(13):265–269. - PubMed
    1. Broder C. C., Xu K., Nikolov D. B., et al. A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Research. 2013;100(1):8–13. doi: 10.1016/j.antiviral.2013.06.012. - DOI - PMC - PubMed
    1. Breed A. C., Meers J., Sendow I., et al. The distribution of henipaviruses in Southeast Asia and Australasia: is Wallace's line a barrier to Nipah virus? PLoS One. 2013;8(4, article e61316) doi: 10.1371/journal.pone.0061316. - DOI - PMC - PubMed
    1. Weingartl H. M., Berhane Y., Caswell J. L., et al. Recombinant nipah virus vaccines protect pigs against challenge. Journal of Virology. 2006;80(16):7929–7938. doi: 10.1128/JVI.00263-06. - DOI - PMC - PubMed

MeSH terms